ethyl 1-(trans-4-methylcyclohexyl)-1H-imidazole-4-carboxylate | 1335139-09-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 1-(trans-4-methylcyclohexyl)-1H-imidazole-4-carboxylate
• CAS: 1335139-09-7
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: JDINZXDXROMVOQ-XYPYZODXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  44.12
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  ethyl 1-(trans-4-methylcyclohexyl)-1H-imidazole-4-carboxylate 在 哌啶 、 lithium aluminium tetrahydride 、 2,2,6,6-四甲基哌啶氧化物 、 palladium 10% on activated carbon 、 水 、 氢气 、 碘 、 碳酸氢钠 、 丙酸 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 环己烷 、 水 、 甲苯 为溶剂， 60.0 ℃ 、101.33 kPa 条件下， 反应 57.0h， 生成 methyl (2S)-5-[(tert-butoxycarbonyl)amino]-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valerate
  参考文献：
  名称：

  CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE

  摘要：

  公开号：

  EP2548871B1
• 作为产物：
  描述：

  trans-4-Methylcyclohexyl amine 、 ethyl 3-(dimethylamino)-2-isocyanoacrylate 反应 4.0h， 以1.90 g的产率得到ethyl 1-(trans-4-methylcyclohexyl)-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE

  摘要：

  公开号：

  EP2548871B1

文献信息

• METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20170291878A1

  公开（公告）日：2017-10-12

  A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.

  一种生产化合物（3）的方法，包括在惰性溶剂中，让化合物（1）与氢气在特定手性配体和钌催化剂的存在下发生反应，或者在之前由手性配体和钌催化剂生成的不对称过渡金属复合催化剂的存在下发生反应。
• Cycloalkyl-Substituted Imidazole Derivative
  申请人：Nagata Tsutomu

  公开号：US20130022587A1

  公开（公告）日：2013-01-24

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R 1 , R 2 , and R 3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R 4 represents a hydrogen atom or a prodrug group; and Y represents —CH 2 —CHR 5 —CH 2 —NHR 6 (wherein R 5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R 6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

  以下是通式（I）所代表的化合物或其药学上可接受的盐，其中A代表一个C3到C12的环烷基，该环烷基可以被一个到三个选自氟基、羟基、C1到C6烷基等的基团所取代；R1、R2和R3各自独立地代表氢原子、氟基或C1到C6烷基；R4代表氢原子或前药基团；Y代表—CH2—CHR5— —NHR6（其中R5代表氢原子、C1到C6烷基或C1到C6烷氧基，R6代表氢原子或前药基团）等，具有极好的TAFIa抑制活性，是治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
• Cycloalkyl-substituted imidazole derivative
  申请人：Nagata Tsutomu

  公开号：US08609710B2

  公开（公告）日：2013-12-17

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

  以下为通式（I）所代表的化合物或其药理学上可接受的盐，其中A代表C3至C12的环烷基，该环烷基可以被氟基、羟基、C1至C6烷基等中的一种至三种取代；R1、R2和R3各自独立地表示氢原子、氟基或C1至C6烷基；R4表示氢原子或前药基团；而Y表示-CH2-CHR5- -NHR6（其中R5表示氢原子、C1至C6烷基或C1至C6烷氧基，而R6表示氢原子或前药基团），等等。该化合物具有出色的TAFIa抑制活性，并可用作治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
• Methods for producing optically active valeric acid derivatives
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US10112908B2

  公开（公告）日：2018-10-30

  A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.

  一种生产化合物（4）的方法，包括让化合物（1）在惰性溶剂中，在特定手性配体和钌催化剂存在下，或在先前由手性配体和钌催化剂生成的不对称过渡金属络合物催化剂存在下，与氢气反应。
• METHODS FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVES
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20190055201A1

  公开（公告）日：2019-02-21

  A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.